Rate-dependent effects of bupropion on nicotine self-administration and food-maintained responding in rats

Stairs, Dustin J.; Dworkin, Steven I.

doi:10.1016/j.pbb.2008.05.014

Cited by 11 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu et al (2008) reported that bupropion increased the ability of a nicotinepaired cue to reinstate behaviour, rather than decreasing this effect as might be expected of an effective smoking cessation treatment. This finding paralleled the effects of bupropion on nicotine self-administration, where rats pretreated with bupropion displayed enhanced nicotine intake (Rauhut et al 2003;Shoaib et al 2003;Stairs and Dworkin 2008), though others have reported no effect of bupropion (Bruijnzeel and Markou 2003;Paterson et al 2008) or a reduction in nicotine self-administration (Bruijnzeel and Markou 2003;Rauhut et al 2005), making it difficult to interpret such findings with confidence. One explanation for these contrasting findings may relate to the ratedependent effects of bupropion on self-administration behaviour, since the rate of responding for the primary reinforcer has been reported to influence the effects of bupropion (Stairs and Dworkin 2008).…”

Section: Introductionmentioning

confidence: 77%

“…This finding paralleled the effects of bupropion on nicotine self-administration, where rats pretreated with bupropion displayed enhanced nicotine intake (Rauhut et al 2003;Shoaib et al 2003;Stairs and Dworkin 2008), though others have reported no effect of bupropion (Bruijnzeel and Markou 2003;Paterson et al 2008) or a reduction in nicotine self-administration (Bruijnzeel and Markou 2003;Rauhut et al 2005), making it difficult to interpret such findings with confidence. One explanation for these contrasting findings may relate to the ratedependent effects of bupropion on self-administration behaviour, since the rate of responding for the primary reinforcer has been reported to influence the effects of bupropion (Stairs and Dworkin 2008). Preclinical data for cannabinoid-1 (CB1) receptor selective antagonists have demonstrated that these compounds reduce both nicotine self-administration and the ability of nicotine-associated cues to reinstate responding for nicotine (Cohen et al 2002(Cohen et al , 2005De Vries et al 2005;Shoaib 2008).…”

Section: Introductionmentioning

confidence: 77%

See 1 more Smart Citation

The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats

et al. 2009

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 77%

Section: Introductionmentioning

confidence: 77%

The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Some studies impose longer timeouts (cf. Neugebauer et al, 2007; Paterson et al, 2003), increase the response requirement, and/or manipulate the food deprivation schedule (Stairs and Dworkin, 2008) in the sucrose experiments meant to parallel drug self-administration studies. Unfortunately, making such a change in reinforcement schedule forces other factors to vary such as temporal pattern of responding and access to the reinforcer.…”

Section: Discussionmentioning

confidence: 99%

Bupropion attenuates methamphetamine self-administration in adult male rats

Reichel

Murray

Grant

et al. 2009

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Bupropion is a promising candidate medication for methamphetamine use disorder. As such, we used a preclinical model of drug-taking to determine the effects of bupropion on the reinforcing effects of methamphetamine (0.025, 0.05 or 0.1 mg/kg/infusion). Specificity was determined by investigating the effects of bupropion on responding maintained by sucrose. In the selfadministration study, rats were surgically prepared with indwelling jugular catheters and trained to self-administer methamphetamine under an FR5 schedule. A separate group of rats was trained to press a lever for sucrose. Once responding stabilized, rats were pretreated with bupropion (0, 10, 30 and 60 mg/kg IP) 5 min before chamber placement in a unique testing order. Following acute testing, rats were then repeatedly pretreated with 30 and 60 mg/kg bupropion. Acute treatments of bupropion dose dependently reduced drug intake for 0.025 to 0.1 mg/kg methamphetamine; sucrose deliveries were only reduced with the high bupropion dose. Repeated exposure to 60 mg/ kg bupropion before the session resulted in a consistent decrease in methamphetamine intake (0.05 and 0.1 mg/kg) and sucrose deliveries. Considered together, this pattern of findings demonstrates that bupropion decreases responding for methamphetamine, but the effects are only somewhat specific.

show abstract

“…The mechanism by which bupropion improves cessation rates in smokers is not fully understood and preclinical studies show a wide range of effects depending on the model or dose used. In some preclinical self-administration studies, acute or repeated bupropion treatment does not have an effect on responding for nicotine (Paterson et al, 2008;10-60 mg/k;Shoaib et al, 2003), while others show increased responding at low doses (9 and 15 mg/kg; Rauhut et al, 2003) and decreased responding at higher doses (Hall et al, 2015;30-75 mg/kg;Liu et al, 2008;Rauhut et al, 2005;Stairs and Dworkin, 2008). Varenicline, on the other hand, is a partial agonist for α4β2 and full agonist for α3β2 and α7 nAChR's (Rollema et al, 2007(Rollema et al, , 2009.…”

Section: Introductionmentioning

confidence: 99%

Individual differences in responding to bupropion or varenicline in a preclinical model of nicotine self-administration vary according to individual demand for nicotine

Kazan

Charntikov

2019

Neuropharmacology

View full text Add to dashboard Cite

Bupropion and varenicline are the top two smoking cessation interventions that are marginally successful in increasing abstinence rates when compared to placebo. Although smokers vary in their history and pattern of tobacco use, there is a significant gap in addressing this individual variability with individually targeted treatments. The present study takes the initial step towards a better understanding of individual differences in treatment outcomes by assessing the effect of bupropion or varenicline on nicotine self-administration in rats. Rats were first assessed for their individual economic demand for sucrose and then for self-administered nicotine (0.03 mg/kg/inf; 2 h sessions). We then examined the effect of bupropion (0, 10, 30, 60 mg/kg) or varenicline (0, 0.1, 1.0, 3.0 mg/kg) pretreatment on individual rates of nicotine self-administration using progressive ratio schedule of reinforcement. Thereafter, rats were subjected to four rounds of extinction and reinstatement tests. We found that individual demand for sucrose did not predict individual demand for nicotine. Acute pretreatments with bupropion or varenicline were most effective at decreasing nicotine self-administration in rats that had a higher demand for nicotine. Rats with higher demand for nicotine also showed higher magnitude of responding in extinction and during nicotine-triggered reinstatement tests. Although the acute treatment protocol employed in this study is an important initial step towards a better understanding of individual treatment effects, future research modeling chronic treatment approaches will be needed to further extend our findings.

show abstract

Rate-dependent effects of bupropion on nicotine self-administration and food-maintained responding in rats

Cited by 11 publications

References 26 publications

The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats

The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats

Bupropion attenuates methamphetamine self-administration in adult male rats

Individual differences in responding to bupropion or varenicline in a preclinical model of nicotine self-administration vary according to individual demand for nicotine

Contact Info

Product

Resources

About